stars 1 stars 2 stars 3

Ikonisys is transforming diagnostic medicine by enabling early, accurate and non-invasive disease detection. Through a unique combination of technology and science, Ikonisys is dedicated to helping physicians and researchers realize the promise of rare cell detection to give patients the best chance of managing their disease. Through its breakthrough fluorescence microscopy platform, Ikonisys continues to develop a stream of oncology tests for a variety of cancers. At the center of the platform is the Ikoniscope20®, a robotic, high-throughput, microscopy system that provides a true “walk away” automated solution. In addition to providing high quality cell images, the platform analyzes the cells of interest, offering an interpretation of the analysis, to facilitate the quick, accurate reporting of the test result. In addition to automating traditional FISH-based tests, the rare cell detection and analysis capabilities of the platform, that facilitates the examination of large complex samples for the clinically relevant cells, make it particularly suitable for circulating tumor cell-based testing.

Ikonisys Questions

The Ikonisys annual revenue was $5.8 million in 2026.

Alessandro Mauri is the CFO of Ikonisys.

24 people are employed at Ikonisys.

The NAICS codes for Ikonisys are [334, 33].

The SIC codes for Ikonisys are [38, 382].

Top Ikonisys Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users